Genentech Gains FDA Approval for Giredestrant Plus Everolimus in Breast Cancer
FDA approves Genentech's giredestrant plus everolimus for ESR1-mutated metastatic breast cancer, with FoundationOne Liquid CDx as mandatory companion diagnostic.


Companion diagnostic co-development has become a regulatory prerequisite in precision oncology, and Genentech's November 16 approval of giredestrant (Wilserdly) illustrates exactly how that architecture now works at the labeling level. The FDA approved the oral estrogen receptor antagonist in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease progressed on prior endocrine-based therapy, and simultaneously authorized the FoundationOne Liquid CDx (F1LCDx) assay as the companion diagnostic to identify eligible patients.
For regulatory affairs teams managing co-development strategies, the approval structure is instructive. Patient selection in the evERA Breast Cancer trial (NCT05306340) depended on ctDNA-based ESR1 mutational status confirmed centrally via F1LCDx, limited to mutations in the ligand binding domain. That assay-specific constraint is now embedded in the indication language, meaning labeling strategy, IVD coordination, and post-market commitments for the diagnostic device are inseparable from the drug's commercial pathway.
Efficacy data from the randomized, open-label, multicenter trial of 373 adults support the benefit-risk profile. In the 207-patient ESR1-mutated subpopulation, giredestrant plus everolimus delivered a progression-free survival hazard ratio of 0.38 (95% CI: 0.27, 0.54; p<0.0001) versus physician's choice of endocrine therapy plus everolimus. Median PFS was 10 months against 5.5 months in the comparator arm; objective response rates were 27% versus 14%. Overall survival data remain immature.
The safety profile carries monitoring obligations relevant to QA and pharmacovigilance leads. Adverse reactions occurring in 20% or more of patients included stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea. Laboratory abnormalities at the same threshold spanned hematologic, hepatic, and metabolic parameters. The prescribing information includes specific warnings for bradycardia and embryo-fetal toxicity, both of which will require documented risk communication and REMS consideration in commercial rollout planning.
The review was conducted under Project Orbis, with Health Canada and Israel's Ministry of Health as co-review partners; applications may still be under review in those jurisdictions. The recommended giredestrant dose is 30 mg orally once daily, administered until disease progression or unacceptable toxicity.
Full prescribing information for Wilserdly will be posted on Drugs@FDA, where regulatory teams can access the complete labeling, including the companion diagnostic authorization parameters that will govern patient identification protocols at the site level.
Source: FDA Drugs, Cancer Approvals via FDA.gov, November 16, 2026.

Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
IDEAYA Biosciences Secures FDA Type C Alignment on Dual-Track IDE849 Registrational Strategy in Neuroendocrine Carcinomas
Cue Biopharma Reports Phase 2 CSU Durability Data and CUE-401 First-in-Human Dosing

Discussion